The chairman asked Jianfeng Pharmaceutical to do three things well.

At the first monthly office meeting of Jianfeng Pharmaceutical Company in 2021 held on January 13, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, put forward the hope and requirements of "reducing cost, expanding volume and speeding up" to the pharmaceutical company.

Reducing costs, I .e. reducing the overall costs of all aspects of production and operation. Jiang Xiaomeng asked pharmaceutical companies to take cost reduction as the main line of production and operation in 2021. Production enterprises should try their best to reduce production costs by improving labor productivity, reducing the purchase price of raw and auxiliary materials, and improving the qualified rate of products. Operating enterprises measure and control operating costs from the perspective of sales revenue and the proportion of employees. At the same time, all units should further strengthen the optimization of institutions and personnel, strive to reduce management costs and improve management efficiency. Expansion, that is, to broaden the market, improve product sales. All departments and units of the pharmaceutical company should cooperate with the sales department to carry out the work, and go all out to strive to expand the sales scale and sales volume. Speed up, that is, speed up product development. Relevant departments should speed up the development of new products, establish corresponding incentive and assessment mechanisms, and strive for the early listing of products with market competitiveness.

Jiang Xiaomeng also hopes that in the new year, Jianfeng Pharmaceutical will truly implement the "three reductions and three improvements" work, strengthen management guidance for subordinate enterprises, and managers at all levels will bravely take responsibility and strive to do a good job in various production and operation work. At the same time, we should do a good job in the prevention and control of the new crown epidemic.

After the meeting, the pharmaceutical company deployed various major tasks for 2021 in accordance with the requirements of the chairman.